Orlistat, a U.S. FDA-approved drug designed for obesity, inhibits pancreatic lipase, thereby preventing the absorption of free FAs from the diet in the intestine. The gene discussed is PNLIP; the disease is obesity due to melanocortin 4 receptor deficiency.